Seattle Genetics, Bayer to develop less symptomatic cancer drug

June 26, 2013

Seattle Genetics (SGEN) inked a deal potentially valued at as much as $520 million in fees with Bayer on Tuesday related to its oncology fighter designed to be less symptomatic compared with traditional chemotherapy. (Fox Business)